P2RY14 and COVID-19: Therefore, Lintzmaier et al. (2021) propose the antagonism of P2Y14 by PPTN as an important therapeutic strategy to mitigate these effects by reducing neutrophil recruitment and NET formation in COVID-19 and the associated lung inflammation.